NY-ESTÉE-LAUDER
4.9.2020 14:02:12 CEST | Business Wire | Press release
Today, The Estée Lauder Companies (NYSE:EL) announced that Tara Simon has joined The Estée Lauder Companies as Senior Vice President, Global General Manager, Too Faced, effective August 31, 2020. She will report to John Demsey, Executive Group President, The Estée Lauder Companies (ELC), and will succeed Eric Hohl, who is departing from the company.
Tara joins Too Faced from ULTA BEAUTY, where she served most recently as Senior Vice President of Merchandising, Prestige Beauty. In this role, Tara was responsible for the successful business model evolution and elevation of ULTA BEAUTY’s luxury brands, spearheading unprecedented growth in the company’s total Prestige Beauty market share. As the leader of ULTA BEAUTY’s Prestige Merchandising Team, Merchandising Strategy Team, and Emerging Brands Team, Tara dramatically increased the number of prestige brands sold through the retailer by attracting exclusive launches from well-established powerhouse brands like M·A·C and Clinique, while also aggressively pursuing and successfully launching smaller start-up brands, resulting in increased consumer engagement and loyalty.
Having partnered closely with Too Faced founders Jerrod Blandino and Jeremy Johnson since 2006, Tara is well versed in the brand’s uniquely vibrant and unabashedly feminine brand equity. She partnered with the founders both during her time at ULTA BEAUTY and previously during her tenure at Sephora, where she served as Director of Business Development and Divisional Merchandise Manager of Color.
“Tara is a visionary strategic leader and brand builder with deep experience in prestige beauty and makeup,” said Mr. Demsey. “She is a force, with unstoppable energy and admirable character. Tara has great respect for the vision, grit and passion with which Jerrod and Jeremy built Too Faced. She will be instrumental in helping to bring the unique brand narrative centered around Jerrod’s inspiring products and experiences to new audiences globally. Her vast expertise and ability to drive winning business results within the specialty-multi prestige beauty space makes her uniquely suited to bring Too Faced to new levels of success.”
As Senior Vice President, Global General Manager, Too Faced, Tara will be responsible for guiding and implementing the brand’s global strategic vision and leading the talented teams across the organization to execute these winning strategies. With her strong background in brand equity and marketing, she will partner closely with Jerrod, Jeremy to leverage a deeper understanding of existing consumers for even stronger affinity and loyalty and also bring new audiences to the brand. At the same time, her operational and retail expertise will enable her to create winning breakthrough service models and merchandising formats by channel to accelerate retail and direct-to-consumer opportunities.
Tara has received several awards and honors in recognition of her exceptional career, including a Cosmetic Executive Women (CEW) Achiever Award in 2018. She sits on Harvard Women’s Leadership Board supporting The Kennedy School’s Women and Public Policy Program, is on the National Board of Directors of CEW, and served on the Advisory Board of The NPD Group.
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, Tommy Hilfiger, M·A·C, Kiton, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, By Kilian, BECCA, Too Faced and Dr. Jart+.
ELC-L
ELC-B
View source version on businesswire.com: https://www.businesswire.com/news/home/20200904005139/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
